EUVIMEDEUVIMED entdecken
Crossref

Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia

Sean M Smith, Dawn Toolan, Monika Kandebo, Joshua Vardigan, Izzat Raheem, Mark E Layton, Jeffrey C Kern, Christopher Cox, Liza Gantert, Kerry Riffel, Eric Hostetler, Jason M Uslaner

The Journal of Pharmacology and Experimental Therapeutics · 2025

DOI: 10.1124/jpet.124.002347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von Sean M Smith und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Inc, Rahway, New Jersey. Electronic address: sean_smith2@merck.com. Hauptthemen laut MEDLINE: Schizophrenia, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Antipsychotic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesAntipsychotic AgentsAnimalsMaleRatsRats, Sprague-DawleyDrug Evaluation, PreclinicalMacaca mulattaAvoidance LearningDizocilpine MaleatePyrimidinesSulfur Compounds

Stichwörter der Autor:innen

Phosphodiesterase 10APsychosisSchizophreniaStriatum

Substanzen

Phosphodiesterase InhibitorsPhosphoric Diester HydrolasesPDE10A protein, ratAntipsychotic AgentsDizocilpine MaleateMK-8189PyrimidinesSulfur Compounds

Autor:innen und Institutionen

  • Merck & Co, Inc, Rahway, New Jersey. Electronic address: sean_smith2@merck.com.
  • Merck & Co, Inc, Rahway, New Jersey.

Zitieren

APA

Smith, S. M., Toolan, D., Kandebo, M., Vardigan, J., Raheem, I., Layton, M. E., Kern, J. C., Cox, C., Gantert, L., Riffel, K., Hostetler, E., & Uslaner, J. M. (2025). Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.124.002347

Vancouver

Smith SM, Toolan D, Kandebo M, Vardigan J, Raheem I, Layton ME, et al. Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1124/jpet.124.002347

BibTeX
@article{Smith2025,
  author = {Smith, Sean M and Toolan, Dawn and Kandebo, Monika and Vardigan, Joshua and Raheem, Izzat and Layton, Mark E and Kern, Jeffrey C and Cox, Christopher and Gantert, Liza and Riffel, Kerry and Hostetler, Eric and Uslaner, Jason M},
  title = {Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  doi = {10.1124/jpet.124.002347}
}
Kostenlos starten →